Person:
SÜMBÜL ŞEKERCİ, BETÜL

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
BETÜL
Last Name
SÜMBÜL ŞEKERCİ
Name
Email Address
Birth Date

Filters

2019 - 201912020 - 202414
Reset filters

Settings

Search Results

Now showing 1 - 10 of 15
  • No Thumbnail Available
    PublicationMetadata only
    Association between the peripheral blood parameters and Alzheimer’s disease in patients with type-2 diabetes mellitus: a case–control study
    (2022-10-01T00:00:00Z) Sümbül Şekerci, Betül; Şekerci, Abdüsselam; Gelişin, Özlem; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM
  • No Thumbnail Available
    PublicationMetadata only
    Low Serum 25-Hydroxyvitamin D Concentration And Alzheimer-s Disease Risk in Patients with Type-2 Diabetes Mellitus
    (2022-05-26T00:00:00Z) Sümbül Şekerci, Betül; Gelişin, Özlem; Şekerci, Abdüsselam; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM
  • No Thumbnail Available
    PublicationMetadata only
    Are Students Using Pharmacological Cognitive Enhancement More Successful?
    (2021-09-08T00:00:00Z) Sümbül Şekerci, Betül; Bektay, Muhammed Yunus; Bildik, Özlem; İzzettin, Fikret Vehbi; SÜMBÜL ŞEKERCİ, BETÜL; BEKTAY, MUHAMMED YUNUS; BİLDİK, ÖZLEM; İZZETTİN, FIKRET VEHBI
    Introduction: The use of psychostimulant drugs to increase academic success is common among young people, especially medical students. However, the effect of psychostimulants on academic success not clear in the current literature. Materials and Methods: A structured online survey was carried out with 431 undergraduate students in different faculties of Medicine in Turkey. Comparisons between groups, correlation and regression analysis about associated variables were made. The academic performance of the students was evaluated with grade point average (GPA) score. Also, academic success, academic anxiety, study performance, sleep quality and pharmacological knowledge levels were questioned with the scale based on self-evaluations. Results: 23 (5.4%) healthy students reported using psychostimulants to improve academic success. There was no significant difference in age, gender, semester, objective (GPA score) and subjective (self-report) assessment of success between users and non-users. But most of the users evaluated that the psychostimulants are useful. Smoking and increased knowledge level of pharmacology are risk factors for psychostimulant use. Conclusion: We could not find a relationship between academic success and pharmacological cognitive enhancement. Psychostimulant use had an positive effect on self-assessment of students. It can support the hypothesis that the psychostimulants has a motivational contribution rather than a purely pharmacological effect. The relationship of psychostimulants with alcohol and smoking should be examined in detail, and users should be questioned in terms of susceptibility to risky behaviors and addiction.
  • No Thumbnail Available
    PublicationMetadata only
    Diyabet ve Prediyabet Hastalarındaki Kognitif Bozulmanın Hipertrigliseridemi İle İlişkisi
    (2023-06-14) Şekerci A.; Sümbül Şekerci B.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    Medication Management and Cognition in Parkinson Disease Patients with Mild Cognitive Impairment
    (2021-05-27T00:00:00Z) Sümbül Şekerci, Betül; Hanağası, Haşmet Ayhan; Bilgiç, Başar; Emre, Murat; SÜMBÜL ŞEKERCİ, BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    Treatment adherence and related factors in Parkinson's disease patients without dementia
    (2022-12-01) Sümbül Şekerci B.; Hanağası H. A.; Bilgiç B.; Emre M.; SÜMBÜL ŞEKERCİ, BETÜL
    Background and Objective: Patients with Parkinson’s Disease (PD) have many risk factors for treatment nonadherence, such as cognitive impairment, depression, polypharmacy, and medication regimen complexity. Adherence in PD should be carefully monitored to accurately assess the patient’s clinical and treatment responseMethod: This is a cross-sectional observational study. Sixty patients who were diagnosed with PD according to the UK PD Association’s Brain Bank criteria and had at least primary school education participated in our study. Patients with a diagnosis of dementia or who received deep brain stimulation, apomorphine infusion, and levodopa/carbidopa intestinal gel therapy were excluded from the study. Main outcome measures: Adherence was evaluated with the 4-item Morisky medication adherence scale. The course of the patients was gauged with the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). MDS-UPDRS subscores are as follows; Part 1: nonmotor experiences of daily life Part 2: motor experiences of daily life Part 3: motor examination Part 4: motor complications. In the evaluation of patients, Schwab and England Activities of Daily Living Rating Scale (SE-ADL) was used for activities of daily living, MoCA for cognitive status, Beck Depression and anxiety scales for mood. The number of drugs used by the patients and LDED were calculated. Results: The mean age of the patients was 62.40 (± 10.25) and 70% of them were male (n:42). There was no significant difference between the adherence of the patients according to the Hoehn and Yahr stages. There was a significant correlation between adherence and depression (p 0.005, r - 0.372), anxiety (0.009 r - 0.357), UPDRS-1 (p 0.006 r - 0.373), UPDRS-2 (p 0.027 r - 0.304), SEADL (p 0.001, r 0.438) scores. When these variables were included in the regression analysis with the enter method, SE-ADL score were found to be significant for predicting adherence (p 0.041, OR 0.328). Conclusion: Motor and non-motor problems of daily life are associated with non-adherence in PD patients without dementia. Treatment of non-motor symptoms such as depression and anxiety may contribute to adherence. Higher independence of patients in daily life increases adherence.
  • No Thumbnail Available
    PublicationMetadata only
    Tedaviye Uyum: Kavramsal Bir Değerlendirme
    (2019-10-01T00:00:00Z) Sümbül Şekerci, Betül; Bildik, Özlem; SÜMBÜL ŞEKERCİ, BETÜL; BİLDİK, ÖZLEM
    ÖZETTedavi uyumuna dair literatürde -compliance-, -adherence- ve -concordance- gibi farklı kavramlar kullanılmaktadır. İngilizce literatürde söz konusu kavramlarda görülen değişimin hastahekim ilişkisinin yapısındaki farklılaşmaya bağlı olduğu bildirilmektedir. Bu konuda farklı terimlerin bulunması nedeniyle karmaşıklık yaşanmakta kavramın nitelik ve nicelik olarak kapsamı hususunda muğlaklık bulunmaktadır. Türkçe literatür değerlendirildiğinde ise bu terimler arasında anlam farkı gözetilmeksizin tümünün uyum ve uyunç kelimeleriyle karşılandığı görülmektedir. Bu çalışmanın amacı literatürümüzde tedavi uyumu konusundaki kavramsal çerçeveyi değerlendirmektir. Bu amaçla öncelikle bahsedilen kavramlar arasındaki farklılıklar ortaya konulmuş ve bu kavramlardaki hasta hekim ilişkisi, sunulan mevcut modeller ışığında incelenmiştir. Türkçe literatürde uyum kavramının kullanımı incelendiğinde de mevcut kavramsal tartışmanın literatürümüze henüz yansımadığı görülmüştür. Bu bağlamda öncelikle Türkiye-de mevcut hasta-hekim ilişkisinin gözden geçirilmesi yoluyla bu kavramsal çerçevenin çizilmesi gerekmektedir. Bununla birlikte hasta-hekim ilişkisine yönelik ülkemizde yapılmış sınırlı sayıdaki çalışmaya dayanarak tek tip bir hasta-hekim ilişkisinin mevcudiyetinden bahsedebilmenin mümkün olmadığı görülmüştür. Sonuç olarak hasta-hekim ilişkisinin uyumsuzluğa yol açan etmenlerden biri olmanın ötesinde, bu kavramı şekillendiren temel dinamiklerden biri olduğu görünmektedir. Hasta-hekim ilişkisine dair sunulan modeller bağlamında bakıldığında, paternalistik bir ilişkiyi yansıtan -compliance- kavramı için -tedaviye bağlılık-, bilgilendirici bir hasta-hekim ilişkisinde ortaya çıkan -adherence- kavramına karşılık -uyum- ve müzakereci bir ilişkiyi vurgulayan -concordance- kavramı için -tedavide iş birliği- ifadelerinin literatürümüz için kullanımı önerilebilir.
  • No Thumbnail Available
    PublicationMetadata only
    Attitudes of Medicine, Pharmacy and Dentistry Students about Psychostimulant Use to Enhance Cognition
    (2021-07-01T00:00:00Z) Sümbül Şekerci, Betül; Bildik, Özlem; Bektay, Muhammed Yunus; İzzettin, Fikret Vehbi; SÜMBÜL ŞEKERCİ, BETÜL; BİLDİK, ÖZLEM; BEKTAY, MUHAMMED YUNUS; İZZETTİN, FIKRET VEHBI
  • Thumbnail Image
    PublicationOpen Access
    Anticholinergic Burden, Polypharmacy, and Cognition in Parkinson's Disease Patients with Mild Cognitive Impairment: A Cross-Sectional Observational Study.
    (2022-10-21T00:00:00Z) Sumbul-Sekerci, Betül; Bilgic, Basar; Pasin, Ozge; Emre, Murat; Hanagasi, Hasmet A; SÜMBÜL ŞEKERCİ, BETÜL; PASİN, ÖZGE
    Introduction: Anticholinergic burden may be an important risk factor for the cognitive impairment. Especially in polypharmacy, even drugs with low anticholinergic effects may contribute to a significant anticholinergic burden. The drugs with anticholinergic effects are used in treatment of motor and nonmotor symptoms of Parkinson’s disease (PD). Therefore, it is important to screen for polypharmacy and anticholinergic burden in PD patients with mild cognitive impairment (MCI). Methods: This cross-sectional study was conducted with 58 patients with PD. PD-MCI was diagnosed according to MDS Level 2 Comprehensive Assessment. Cognitive performance (attention – working memory, executive functions, language, memory, and visuospatial functions) of patients was evaluated. The anticholinergic burden was scored by Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Risk Scale (ARS), and Anticholinergic Drug Scale (ADS). Results: There was no significant difference in anticholinergic burden between PD-MCI and PD-normal cognition. A significant concordance was observed between ACB, ARS, and ADS scores (p < 0.001; Kendall’s W = 0.653). While the variable predicting anticholinergic burden was the total number of drugs for ACB and ADS scales, it was the number of antiparkinson drugs for ARS scale. Conclusion: Patients with PD are at high risk for polypharmacy and anticholinergic burden. Anticholinergic burden should be considered in the selection of drugs, especially for comorbidities in patients with PD. No significant correlation was found between the cognition and anticholinergic burden in patients with PD-MCI. Although the risk scores of antiparkinson and other drugs were different among the 3 scales, significant concordance was observed between scales.
  • No Thumbnail Available
    PublicationMetadata only
    FARMASÖTİK BAKIM HİZMETİNİN DİYABET PROGNOZUNA ETKİLERİNİN DEĞERLENDİRİLMESİ
    (2022-05-07T00:00:00Z) Kutluay, Nur Bucu; Bektay, Muhammed Yunus; Sümbül Şekerci, Betül; Şekerci, Abdüsselam; İzzettin, Fikret Vehbi; BEKTAY, MUHAMMED YUNUS; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM; İZZETTİN, FIKRET VEHBI